Rigel Pharmaceuticals (RIGL) Set to Report Q4 FY2025 Earnings After the Bell — Here’s What to Expect
Consistency Ratings
| Metric | Q4 FY2025 Est | Q4 FY2024 Actual | YOY Change |
|---|---|---|---|
| Net worth | ~$75–85M | ~$57.6M | +30-48% |
| EPS | ~$1.60–1.80 | ~$0.8 | Important expansion |
Analyst consensus: Strong Buy (5 analysts). Average price target: $43.20 compared to the current price of $34.62.
Key metrics to watch
1. Full Year Revenue Versus Average of $299M
The FY2025 full-year estimate of $299.06M represents a 67% jump from FY2024’s $179.28M. TTM revenue through September 2025 was $282.08M, which means Q4 needs to bring in about $17M more than TTM pace – possible but dependent on milestones and master payment schedules. The rhythm of the full year ensures that the inflection is real; the miss would raise questions about whether the FY2024–2025 jump was driven by one-time payments versus a longer-term stream of royalties.
2. Earnings per share — Profit volatility
FY2025 EPS is estimated at $6.75 compared to FY2024’s $0.99 – a near 6x jump that would indicate a real profit shift. Rigel postponed the stock split, which pushed the dividend count to 18M shares, so the EPS numbers could be boosted. The key question: is this level of profit sustainable, or was it driven by historic receipts that will never appear again?
3. TAVALISSE Royalty Trajectory
TAVALISSE gains from the US ITP market is Rigel’s long-term cash flow. Investors will want to see if revenue is growing (expanded subscriber base, new patient starts, potential label expansion negotiations) or rising. Any color in the performance of TAVALISSE in nearby indications (warm autoimmune hemolytic anemia is an ongoing area of interest) would be a reasonable catalyst.
4. Discipline of Operating Expenses
As a specialty pharmaceutical company, Rigel’s ability to generate revenue is highly dependent on keeping SG&A and R&D costs under control while profitability scales. Any material increase in operating costs – especially if it is linked to new clinical investments without significant milestones in the near future – could weigh on the FY2026 profit outlook.
5. New Licensing / Pipeline Development
Rigel’s next move beyond the benefits of TAVALISSE and GAVRETO requires new candidates or additional licensing partnerships. Any announcement – even an early stage – of new collaborations, new indications for existing drugs, or milestones from existing agreements can be a catalyst for a company with this level of analyst scrutiny and a 5-person analyst base that is essentially fully operational.
Situational Analysis
| The situation | Q4 revenue | FY2025 EPS | The key driver | Stock reaction |
|---|---|---|---|---|
| **Bull** | $85M | >$7.00 FY | Milestones + solid payouts | +10% to +18% |
| **Base** | ~$75–82M | ~$6.50–7.00 FY | Solid benefits, milestones in line | Down to +6% |
| **Bear** | <$70M | <$6.00 FY | Milestone time has changed, payouts are lower | -8% to 15% |
Bull case: Q4 revenue cleared $85M, the full year comfortably beat $299M, and management provided guidance for FY2026 that pointed to continued growth in royalties and potentially significant new fees. EPS above consensus confirms the profitability story.
Base case: Q4 comes in the $75–82M range, full year comes in around $295–305M, and EPS is broadly in line. FY2026 guidance implies modest growth but no acceleration. The stock has close current levels.
Bear case: Milestone’s timing changed in Q4, resulting in a revenue miss and a full-year deficit of less than $285M. EPS falls below $6.00. Management’s commentary for FY2026 is cautious, raising concerns that the FY2025 spike was more milestone-driven than royalty-driven and therefore unsustainable.
Context: Latest trends
The story of Rigel’s transformation is true but convoluted in nature. Royalty-based and milestone income is patchy in nature – a single affiliate fee can swing dramatically in either direction. The company turned in positive free cash flow in FY2024 ($31.44M), which is a milestone after years of cash burn, and FY2025 earnings volatility appears to be systematic rather than one-off if TAVALISSE’s base continues to grow.
With 18 million shares outstanding post-split and a stock price of $34, Rigel’s market cap is estimated at $624M – still relatively soft compared to the level of revenue and profit. A buy consensus of 5 analysts and a $43 price target suggest room for a re-rate if tonight’s results confirm earnings are strong. The main risk is that FY2026 earnings potential is significantly lower than the FY2025 estimate of $6.75 EPS if milestone payments do not repeat and TAVALISSE royalties plateau.
The earnings call starts after the market closes. Follow AlphaStreet for live coverage and analysis of post-earnings results.
Source: StockAnalysis, AlphaStreet Earnings Calendar. Estimates as of March 3, 2026. Consensus figures are estimated and subject to revision.
